BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN)

BNP Paribas Financial Markets boosted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 221.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,546 shares of the company’s stock after buying an additional 5,890 shares during the quarter. BNP Paribas Financial Markets’ holdings in UroGen Pharma were worth $109,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. FMR LLC lifted its position in shares of UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company’s stock valued at $293,000 after acquiring an additional 19,670 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in UroGen Pharma by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company’s stock worth $1,149,000 after purchasing an additional 7,576 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of UroGen Pharma during the third quarter worth $155,000. GSA Capital Partners LLP acquired a new stake in shares of UroGen Pharma in the third quarter valued at about $249,000. Finally, Rice Hall James & Associates LLC lifted its stake in shares of UroGen Pharma by 273.6% in the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock worth $3,453,000 after buying an additional 199,110 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on URGN. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Friday, December 6th. Guggenheim started coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. Finally, Oppenheimer reiterated an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Price Performance

URGN stock opened at $10.79 on Thursday. UroGen Pharma Ltd. has a 52-week low of $10.60 and a 52-week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a market cap of $253.07 million, a price-to-earnings ratio of -3.43 and a beta of 1.06. The business has a fifty day moving average of $12.11 and a two-hundred day moving average of $13.86.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. As a group, research analysts anticipate that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.